Certified by Founder Lodge
Abingworth
United Kingdom - London, UK
INVESTOR
1 Disclosed Funding Rounds $150,000,000
5 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber man
| Company | Date | Round | Raised |
|---|---|---|---|
 Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Myricx Bio |
July, 09 ,2024 | Series A | $115,246,800 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Alvara Protocol | $10,000,000 | (Oct 22, 2024)
Rollstack | $11,000,000 | (Oct 22, 2024)
Biological Lattice Industries | $1,800,000 | (Oct 22, 2024)
SchooLinks | $80,000,000 | (Oct 22, 2024)
MyFO | $3,500,000 | (Oct 22, 2024)
